---
layout: default
title: Serine
parent: 僅模型預測 (L5)
nav_order: 898
evidence_level: L5
indication_count: 10
---

# Serine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Serine: From No Established Indication to Familial Visceral Myopathy (Preliminary Signal)

## One-Sentence Summary

Serine is an unregistered amino acid compound with no approved therapeutic indication or documented mechanism of action in the current dataset. The TxGNN model's top prediction points to **Familial Visceral Myopathy**, but this association is currently supported by **zero clinical trials** and **zero publications** — it is a pure knowledge-graph inference with no external validation.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not established (no approved indication on record) |
| Predicted New Indication | Familial Visceral Myopathy |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available, and no approved therapeutic indication has been recorded for Serine in the regulatory dataset. Serine is a non-essential amino acid known to participate in protein synthesis, phospholipid (phosphatidylserine) biosynthesis, and one-carbon/folate metabolism, but without confirmed clinical indication or MOA documentation, no mechanistic bridge to familial visceral myopathy (a rare hereditary disorder of gastrointestinal smooth-muscle function) can be established from the evidence on hand.

The TxGNN score (99.99%, rank 292) reflects high confidence *within the model's internal graph structure*, but this is not corroborated by any independent clinical or literature signal — the evidence pack explicitly notes this is "pure knowledge-graph inference, no biological plausibility established."

**A note on the lower-ranked candidates:** several of the other 9 predicted indications (e.g., *intestinal obstruction*, *angle-closure glaucoma*) initially appear literature-rich, but closer review shows these are largely false positives caused by textual overlap between "Serine" (the amino acid) and unrelated terms such as "serine protease" or "PRSS56" (a gene encoding an enzyme with "serine" in its name). None of the reviewed trials or papers describe pharmacological use of the amino acid Serine for these conditions.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Singapore Market Information

Serine has **no marketed products or authorization registrations** in Singapore (0 licenses on record). No dosage form, brand name, or approved indication data is available.

---

## Safety Considerations

No safety data (key warnings, contraindications, or drug-drug interactions) is currently available for Serine in this dataset.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked predicted indication (familial visceral myopathy) has no supporting clinical trials or literature, the drug's mechanism of action is undocumented, and it currently has no market presence or safety profile in Singapore. This is a model-only signal that does not meet the minimum evidence bar to proceed.

**To proceed, the following is needed:**
- Mechanism of action data from DrugBank or primary pharmacology literature (currently blocking — DG002)
- Regulatory label / package insert data (warnings, contraindications) — currently blocking (DG001)
- Disease-specific pharmacological or preclinical studies that clearly distinguish the amino acid Serine from unrelated "serine protease"/gene-name matches
- Confirmation of whether any jurisdiction has approved or is investigating Serine for a specific indication, to establish a baseline "original indication" for comparison
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

